Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-169"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Information on medicinal products (Community code relating to medicinal products) - Information on medicinal products (Community procedures for the authorisation and supervision of medicinal products) (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20101122.17.1-169"2
lpv:hasSubsequent	lp_eu:2010-11-22-Speech-1-1702
lpv:speaker	lp:Françoise Grossetête2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 substitute; Delegation for relations with Australia and New Zealand (2009-09-16--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; ITRE (2009-07-16--2012-01-18)3 member; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 unknown; Union pour un Mouvement Populaire (2009-07-14--2014-06-30)3
lpv:translated text	". Madam President, I would like to congratulate our rapporteur, Mr Fjellner, on the excellent work he has been doing for several months on these two reports. I say this especially because we have been waiting years for this text. The oldest MEPs among us will remember that, back when the pharmaceutical legislation was being revised, we wanted to talk about teaching patients about medicinal products and treatments, but that, unfortunately, there was some confusion between information and advertising. Nowadays, information must not be allowed to be disguised advertising and, in fact, the emphasis in these reports is no longer on the right of companies to convey information but on the right of patients to access it. The rationale is therefore completely different, and that is why patients are the priority. Moreover, we say ‘no’ to unsolicited information, a move that will reduce the distribution channels and thus the risks of advertising. Patients themselves will search for the information they want, which will not be forced on them, via the radio or television, newspapers or magazines. That, in fact, is what makes it different from advertising. Some information will therefore need to be pre-vetted. Such pre-vetting must be carried out by national authorities, and it must allow for the creation of specialist, objective websites, and the use of specific printed materials, as Commissioner Dalli has explained. All the conditions are therefore in place for ensuring good quality information, objective information, information for which patients have long been waiting. This is why the Council absolutely must fulfil its responsibilities and agree to it, because we cannot allow just any information to be found on websites. We have been waiting for 10 years: 10 years for the Council to make its decision."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph